Clinical Takeda Pharmaceutical gets FDA nod for lung cancer drug...

Takeda Pharmaceutical gets FDA nod for lung cancer drug Exkivity


The U.S. Food and Drug Administration had approved Takeda Pharmaceutical Co.’s drug, Exkivity, to treat a particular type of lung cancer, the Japanese pharmaceutical company announced on 15th September.

The drug has been approved only for patients having a particular gene mutation in non-small cell lung cancer (NSCLC) known as EGFR Exon 20 insertion, whose disease has grown during or after the chemotherapy.   

Exkivity’s approval from the FDA was explicitly based on some affirmative and meaningful results yielded from early-to-mid stage trials carried out on 114 patients having NSCLC, over a period of 18 months on average, the company said, which is subjected to the verification and description of clinical benefit through confirmatory trials.

However, the drug is marketed with a boxed warning indicating potential risks relating to the heart toxicity, heart rhythm disturbance and lung diseases.

According to the World Health Organization, NSCLC is the most common type of lung cancer constituting up to 85% of the estimated 2.2 million cases of lung cancer diagnosed every year globally.   

Latest news

Zealand Pharma and Iktos collaborate to develop AI Technology for Peptide drug design

Specialists in artificial intelligence for new drug design, Iktos announced a research partnership with Zealand Pharma to...

UK’s NICE makes recommendation for Imlifidase by Hansa Biopharmaceutical

With the National Institute for Health and Care Excellence’s (NICE) recommendation for the use of imlifdase, over...

Heart failure drug by Cytokinetics delayed – FDA wants more time to review

The Food and Drug Administration requires more time to study Cytokinetics’ omecamtiv mecarbil following analysis of some...
- Advertisement -

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you